Product
Vesicare & Betmiga
Name
VESIcare
INN Name
solifenacin succinate
FDA Approved
Yes
1 clinical trial
1 organization
1 indication
1 document
Indication
HealthyClinical trial
An Open Label Randomized, Single Dose, Three-way, Partial Replicate Bioequivalence Study to Determine the Bioequivalence of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg Film Coated Tablets & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)Status: Completed, Estimated PCD: 2022-07-25
Document
DailyMed Label: VESIcareOrganization
Astellas Pharma US, Inc.